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Background/aim: Post-ERCP cholangitis (endoscopic retrograde cholangiopancreatography) and associated sepsis can be lifethreatening. Despite the wealth of studies on post-ERCP pancreatitis risk factors, there is limited data on post-ERCP cholangitis. This
study aimed to investigate the rates, predictors, and outcomes of post-ERCP cholangitis.
Materials and methods: A retrospective review of 452 ERCP cases performed by a single endoscopist at a tertiary center between
March 2019 and February 2021 was performed. Patient-related, organizational and periprocedural factors that could affect post-ERCP
cholangitis were evaluated. Predictors of post-ERCP cholangitis were determined by multivariable analysis.
Results: The post-ERCP cholangitis rate was 19.5%. Cholangiocarcinoma (OR 15.72, CI 2.43–101.55, p = 0.004), the American Society
of Anesthesiologist Score (ASA) (OR 2.87, CI 1.14–7.21, p = 0.024), an increase in bilirubin after ERCP (OR 1.81 CI 1.01–3.22, p =
0.043), body mass index (OR 1.15, CI 1.00–1.33, p = 0.04) and procedure duration (OR 1.02, CI 1.00–1.05, p = 0.049) were predictors of
post-ERCP cholangitis. Biliary stone extraction using a balloon was found to be protective against cholangitis (OR 0.18, CI 0.05–0.60, p
= 0.005). Sepsis rate related to post-ERCP cholangitis was 2.4% and death 1%.
Conclusion: Patients who undergo ERCP procedures due to malignant bile duct stenosis, have a high ASA score and BMI, and have a
long procedure time should be paid attention and closely monitored. Further research is needed to determine whether measures aimed
at the identified risk factors will reduce the incidence of post-ERCP.
Key words: Post-ERCP cholangitis, malignant biliary obstruction, ASA score, procedure duration

1. Introduction
The endoscopic retrograde cholangiopancreatography
(ERCP) procedure is widely used with considerable
success in the treatment of bile duct and pancreatic
pathologies in gastroenterological practice [1]. This
effective procedure is the leading therapeutic tool for
dealing with biliary stones, as well as with benign and
malignant strictures [2]. With the widespread use of
magnetic resonance cholangiopancreatography and
endoscopic ultrasonography, the rate of diagnostic ERCP
and ERCP-related complications have declined, while the
preference for therapeutic ERCP has increased. However,
life-threatening complications such as pancreatitis,
cholangitis, bleeding and perforation, make this procedure
more challenging in gastroenterological practice [3]. PostERCP pancreatitis rates and prevention methods have
been extensively studied, and complication rates have
been found to decrease through taking the appropriate
measures. However, data on the factors that may predict

post-ERCP cholangitis are limited, and further studies are
needed on this subject.
Post-ERCP cholangitis is one of the most common
complications observed after ERCP [4]. Cholangitis
rates after ERCP vary between 1% and 7% [5,6] in the
general population where all ERCP complications are
reported, but this rate increases to 29.2% in patients
who undergo ERCP and who have had a biliary stent
inserted due to the indication of cholangiocarcinoma
[7]. Post-ERCP cholangitis is the leading cause of the
majority of septic complications after ERCP [8]. In a large
multicenter, nationwide study, post-ERCP cholangitis was
an independent predictor of post-ERCP sepsis. In this
study, the rate of post-ERCP sepsis was 8.8% and related
mortality was 7.5% [9]. To prevent such catastrophic
clinical outcomes, it is necessary to know the rates of postERCP cholangitis, predict which patients are at high risk
of developing post-ERCP cholangitis and take precautions
for this patient group. According to the limited number
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of previous studies, age, prior history of ERCP, hilar
obstruction [10], cancer diagnosis, multiple biliary
stent insertion, and lower albumin levels [11] have been
identified as independent factors for the development of
post-ERCP cholangitis. However, compared to the more
widely studied post-ERCP pancreatitis, there is a shortage
of data related to factors that influence post-ERCP
cholangitis.
This study aimed to ascertain post-ERCP cholangitis
rates and describe the factors leading to cholangitis, in
order to identify the interventions that can reduce postERCP cholangitis and sepsis rates in the future.
2. Methods
2.1 Design and settings
We reviewed ERCP procedures retrospectively to
determine the rates and predictors of post-ERCP
cholangitis in an inner-city tertiary health care facility
between March 2019 and February 2021. All consecutive
ERCP patients older than 18 years of age who gave written
consent for the procedure were included in the study.
Clinical histories, physical examination notes, laboratory
values and ERCP reports of the patients were reviewed
on the basis of the hospital’s electronic records. Excluded
from the study were patients diagnosed with cholangitis
before ERCP, patients who had been referred to our
endoscopy unit for ERCP from another hospital and who
were followed up at an external center after the procedure,
patients who underwent cholangioscopy procedures but
had inconsistent electronic medical records, as well as
patients who, before the ERCP procedure, were already
receiving antibiotics for some reason.
Over the ten years under examination, ERCP
procedures at our hospital were performed by a total of
thirteen different endoscopists, including five academic
staff and eight fellows. Our ERCP unit was renovated
two years ago and moved to a different location. Scope
reprocessing procedures and logistics factors have
changed. Because these factors may change the outcome
of cholangitis, only data from an experienced endoscopist
in the past two years was analyzed.
2.2 Definition of variables
Post-ERCP cholangitis served as the dependent variable,
whereas the following variables were considered
independent factors in post-ERCP cholangitis: sex,
age, body mass index (BMI), hospitalization status,
hospitalization duration (in days), comorbidities
(hypertension, diabetes mellitus), number of the previous
ERCPs, American Society of Anesthesiologists Score
(ASA), tumor and stenosis localization of the biliary
system, total procedure duration, ERCP cannulation
technique, stone extraction technique (balloon or basket),
and biliary stenting. Post-ERCP cholangitis is defined as
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abdominal pain, jaundice, and a body temperature of 38
degrees Celsius (℃) or above. Patients were accepted as
post-ERCP cholangitis in the presence of the following
findings in absence of any other infectious reason;
leukocytosis >9000/µL, CRP > 3 mg/L, total bilirubin
levels > upper limit of normal (ULN). The duration
of the procedure was calculated retrospectively from
the fluoroscopy and endoscopy records. The difference
between the time of the first recorded image and the last
was considered procedure time. The increase in bilirubin
after the procedure was accepted as an elevation in the
amount of bilirubin compared to the preprocedural
levels. ASA scores were determined during preoperative
evaluation at the anesthesiologist’s office before the ERCP
appointment. ASA scores are as follows: I- a normal
healthy patient, II- a patient with mild systemic disease,
III- a patient with severe systemic disease, IV- a patient
with severe systemic disease that is a constant threat to life,
V- a patient who is not expected to survive without the
operation, and VI- a declared brain-dead patient whose
organs are being removed for donor purposes. Patients
with ASA IV and above were intubated. Because of the
higher periprocedural risk, the procedure was performed
in the operating room close to the intensive care unit,
instead of in the usual endoscopy suite.
2.3 ERCP procedure
ERCP procedures were performed under deep sedation,
using propofol and midazolam. Heart rhythm, blood
pressure, and oxygen saturation were closely monitored
by the anesthesia team. After 6 h of observation following
the ERCP procedure, patients without complaints and
with stable vital signs were discharged and followed up
on an outpatient basis. Prior to discharge, the patient
and caregivers were verbally informed of the possible
complications after ERCP. In case of any complaints, they
were asked to inform the hospital via telephone or admit
themselves to our hospital. The day after the procedure,
all ERCP patients were followed up with a phone call.
Patients who developed cholangitis in the long term
and were admitted to a different hospital were followed
up retrospectively using the e-nabız system for 30 days,
and the results of the examination were evaluated. The
e-nabız system is the national electronic medical record
system through which doctors can access examinations
performed all over Turkey.
2.4 Statistical analysis
All statistical analyses were performed using IBM SPSS
Statistics 20.0 for Windows (IBM Corporation, Armonk,
NY, USA). Kolmogorov–Smirnov and Shapiro–Wilk’s tests
were used to assess the assumption of normality. Numeric
variables were presented with mean ± standard deviation
or median (25th–75th percentile). Categorical variables
were summarized as counts (percentages). Comparisons
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of numeric variables between groups were carried out
using the Mann–Whitney U test, since the normality
assumption was not met. Association between two
categorical variables was examined using the chi-square
test. Logistic regression analysis was used to determine the
factors that affected the outcome variable. All statistical
analyses were carried out with 5% significance, and a twosided p-value <0.05 was considered statistically significant.
2.5 Ethical considerations
This study protocol was reviewed and approved by the
Kocaeli University Ethical Committee of Clinical Research
(Identifier: GOKAEK-2021/13.15 Project number:
2021/219). The study was not funded by any organization.
We conducted this research in accordance with the 1964
Helsinki Declarations.
3. Results
3.1 Patients and clinical characteristics
A total of 452 ERCP patients were initially identified
during the 23-month study period, but only 296 patients
were included in the analysis (Figure). Of these patients,
58 (19.5%) were diagnosed with post-ERCP cholangitis.
One hundred and sixty-eight (56.8%) of the patients were

men, the mean age of the study population was 60.64 ±
15.9 years, and 212 (71.6%) of the patients were inpatients
(Table 1). One hundred and seventeen (40%) of the
patients were naive for ERCP, while the rest of the patients
experienced ERCP procedure one or more (Table 2). ERCP
procedures lasted for a median of 21 min (IQR: 11.25–35).
Patients with a diagnosis of cholangitis received inpatient
treatment for a median of 5 days (IQR: 2.25–20.75). A total
of 47 (81%) of the patients were diagnosed with cholangitis
48 h after the procedure. Post-ERCP sepsis developed
in 7 patients (2.4%), and 3 of those patients died within
30 days after ERCP. The first who died was a 70-year-old
male patient diagnosed with primary pancreatic head
carcinoma, who had had a metal stent inserted by ERCP.
He was found to be positive for COVID-19 on the 5th day
after the procedure and died due to sepsis on the 9th day.
The second patient, an 81-year-old female, had a previous
history of diabetes mellitus type 2, hypertension, and
breast carcinoma. She died as a result of septic shock on
the 4th day after ERCP and after the insertion of a plastic
stent, which was intended as a way of dealing with the
periampullary mass. Finally, a biliary plastic stent was
inserted by ERCP in an 87-year-old female patient with
a diagnosis of pancreatic head carcinoma, and the patient

Figure. Flowchart of the study population.
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Table 1. Baseline characteristics of patients (n = 296).
N

(%)

Sex (male)

168

56.8

Age*

60.6 ± 15.9

(18–94) **

BMI*

26 ± 4.3

(17–46) **

Hospitalization (days)*

5 ± 11

(1–60) **

Smoking

59

19.9

Malignancy

86

29.1

Cholecystectomy

72

24.3

In-patients

212

71.6

Outpatients

84

28.4

Hypertension

114

38.5

Diabetes mellitus

95

32.1

None

117

39.5

Once or twice

127

42.9

Three time or more

52

17.6

ASA I

55

18.6

ASA II

147

49.7

ASA III

82

27.7

ASA IV

12

4.1

Hospital stays

Comorbidities

Number of ERCP

ASA scores

ASA: American Society of Anesthesiologists, ERCP: Endoscopic
Retrograde Cholangiopancreatography, BMI: Body Mass Index kg/
m2, *(mean ± SD), ** minimum-maxiımum values.

who developed cholangitis and sepsis after the procedure
died ten days afterwards.
3.2 Univariate analysis of factors associated with the
cholangitis
According to our univariate analysis, patients with high
BMI, an increased level of bilirubin after the procedure,
long total procedure time, malignant disease, a high
ASA score or plastic stent placement during ERCP, had
a statistically significantly higher rate of post-ERCP
cholangitis. Significantly less cholangitis was detected in
patients who underwent a stone extraction with a balloon.
There was no statistically significant difference in terms
of sex, age, smoking, hypertension, diabetes mellitus type
2, antibiotic use before the procedure, cholecystectomy
history, ERCP indication, sphincterotomy, number of
placed stents, multiple ERCP history, and post-ERCP
cholangitis (Table 3).
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3.3 Multivariable analysis of factors associated with the
cholangitis
The parameters that were found to be statistically
significant in the univariate analysis were analyzed in the
multivariable logistic regression model. The strongest
independent predictor of post-ERCP cholangitis was
cholangiocarcinoma (OR 15.72, CI 2.43–101.55, p =
0.004). In addition, ASA score, bilirubin increases after
ERCP, BMI, and total procedure time were independent
predictors of post-ERCP cholangitis. Biliary stone removal
with the balloon was found to be a factor that protected
against post-ERCP cholangitis. The association between
metal or plastic stent placement, hospitalization duration,
and cholangitis lost its significance in the multivariable
analysis (Table 4).
4. Discussion
Post-ERCP cholangitis is a severe complication that
can lead to sepsis and death if not treated promptly and
appropriately. We retrospectively assessed post-ERCP
cholangitis and determined post-ERCP cholangitis
predictors for the additional targeted protective measures.
We found that almost one-fifth of the patients examined
developed cholangitis after ERCP. Our post-ERCP
cholangitis rates were in the range of 1%–29.2% and
comparable with the previous studies [7,12,13]. We found
that the presence of cholangiocarcinoma, total procedure
time, ASA score, bilirubin increases after ERCP, and BMI
were independent predictors of post-ERCP cholangitis.
Our post-ERCP cholangitis rates are relatively high
compared to the rates in those studies that examined general
post-ERCP complications (ranged between 1% and 5%)
[13,14]. In previous research, the definition of post-ERCP
cholangitis was quite heterogeneous. For example, in one
study, right upper quadrant pain, fever, leukocyte count >
12,000/µL, and CRP > 3 mg/L, ALT, and total bilirubin >
ULN were considered acute cholangitis [15]. In that study,
all patients were given prophylactic antibiotics before the
procedure, and the highest rate of acute cholangitis was
found to be 4.8%. In another study, fever of 37.8 ℃ and
above, WBC > 9000/µL or <4000/µL, and CRP increase
within seven days after ERCP, were regarded as indices of
post-ERCP cholangitis, and post-ERCP cholangitis rates
were calculated as 40.7% after plastic stent placement
in patients with cholangiocarcinoma [16]. In our study,
we accepted patients who had cholangitis in cases of
leukocytosis, elevated total bilirubin, and CRP > ULN if
there was no other cause of infection; we also looked for
fever (37.8 ℃), abdominal pain, and jaundice classical
triad. Firstly, due to this broad definition, our post-ERCP
cholangitis rates may have been high. Secondly, most of
our study population consisted of cholangiocarcinoma
and patients who received a biliary stent, so our
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Table 2. Baseline procedure characteristics (n = 296).
N

(%)

Periampullary Tm

6

2

Cholangiocarcinoma

62

21.0

Pancreas Ca

45

15.2

Choledocholithiasis

126

42.6

Stent revision

43

14.5

Hilar metastasis

14

4.7

Sphincterotomy

225

76

Precut papillotomy

37

12.5

Extraction balloon

192

64.9

Basket

50

16.9

Brush cytology

18

6.1

No stent

119

40.2

One stent

140

47.3

Two stent

37

12.5

Plastic stent

145

81.9

Metallic stent

32

18.1

CBD diameter (mm)*

12.4 ± 5.2

(5–30) **

Procedure duration (min)*

24.5 ± 17.9

(2–130) **

ERCP indications

Techniques of ERCP

Number of biliary stents

Stent type

ERCP: Endoscopic Retrograde Cholangiopancreatography, Tm:
Tumor, Ca: Carcinoma, CBD: Common Bile Duct, min: minutes,
mm: millimeter, *mean ± SD, **minimum-maxiımum values.

cholangitis rate is comparable to that in studies whose
subjects also experienced cholangiocarcinoma and stentrelated cholangitis. Lastly, our study population consisted
of tertiary university hospital patients. Thus, patients with
more severe conditions may have been included. It is
worth noting that our sepsis and mortality rate was low
despite the high cholangitis rates. This suggests that postERCP cholangitis was recognized in a timely manner, and
that adequate and critical treatment was provided.
The novel finding of our study was that ASA grade
was an independent and strong predictor of post-ERCP
cholangitis. Coton et al. concluded that poorer health
conditions and ASA grades III–V were related to severe and
fatal outcomes of ERCP [17]. Kwak et al. also concluded
that ASA grades IV and V were related to overall postERCP complication. Additionally, ASA III was related to
post-ERCP pancreatitis [18]. The ASA grade may reflect
patients who are more vulnerable to ERCP complications,

as it serves as a classification of a patient’s overall wellbeing. Therefore, one could expect advanced ASA grades
to be linked to cholangitis. Our results revealed for the
first time that ASA grade III was an independent predictor
of post-ERCP cholangitis. In support of this, a moderate
or severe illness which was previously indicated by the
advanced ASA grade was associated with the surgical
site infection after elective rectal cancer operation [19],
shoulder arthroplasty [20], and prosthetic joint infections
following the knee replacement [21]. For patients with
an advanced ASA grade who plan to undergo the ERCP
procedure, special care should be taken in terms of postERCP cholangitis, and these patients might be candidates
for prophylactic antibiotic therapy.
We also found that BMI and the total procedure time
for cholangiocarcinoma were independent risk factors
for post-ERCP cholangitis. Our results confirmed that
cholangiocarcinoma was an independent risk factor
leading to post-ERCP cholangitis [10,22]. In case of hilar
obstruction, it may not always be possible to provide
biliary drainage, or this drainage may be insufficient due to
stricture. In addition, even if a stent can be placed proximal
to the stenosis, early stent occlusion is most common at
hilar localization [23], and post-ERCP cholangitis may
develop subsequent insufficient drainage. As a result of a
complete or partial obstruction in the biliary system due
to cholangiocarcinoma, the biliary pressure rises and,
accordingly, cannulation becomes difficult during ERCP.
In addition, the transition to the proximal of stenosis
is challenging, and the duration of the procedure is
prolonged. Prolonged procedure time can cause mucosal
damage, and bacterial endotoxins can easily penetrate
the deteriorated blood-biliary to the mucosa to enter the
systemic circulation and cause bacteremia. In line with a
previous study, we found that prolonged procedure time
increases the risk of cholangitis [24]. Additionally, the
possibility of developing cholangitis rises with increasing
BMI. It is known that patients with a high BMI are
more vulnerable to hospital and community-acquired
infections as a result of impaired immune function [25].
Patients with a high BMI tend to have metabolic disorders,
are vulnerable to infections, and are at greater risk for
nosocomial infections, especially after the interventional
procedure.
Taking appropriate measures for the defined risk
factors associated with post-ERCP cholangitis could
result in a decrease in the cholangitis rate and enhance
positive outcomes. Kim et al. compared the effectiveness of
preprocedural intravenous moxifloxacin and ceftriaxone
with patients undergoing ERCP. Post-ERCP cholangitis
occurred in only 2.3% of the moxifloxacin group and
4.8% of the ceftriaxone group. There was no statistically
significant difference between groups [15]. According to
the American Society for Gastrointestinal Endoscopy
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Table 3. Comparison of risk factors for post-ERCP cholangitis.

Sex
Male
Female
Age *
BMI*
In-patients
Hospitalization (days)*
Smoking
Hypertension
Diabetes mellitus
Malignancy
Cholecystectomy
Post-ERCP fever
Increase in bilirubin (mg/dL) *
CBD diameter (mm)*
Procedure duration (min)*
Sphincterotomy
Precut papillotomy
Extraction balloon
Basket
Number of biliary stents
No stent
One stent
Two stent
Stent type
Plastic stent
Metallic stent
Number of ERCP
None
Once or twice
Three-time or more
ASA scores
ASA I
ASA II
ASA III
ASA IV
Tumor localization
Pancreatic head
CBD
Periampullar

Patients without cholangitis
(n = 238)

Patients with cholangitis
(n = 58)

N / (%)

N / (%)

p value

0.981a
135 (56.7)
103 (43.3)
60.4 ± 16 (18-94) **
25.7 ± 4.3 (17–46) **
161 (67.6)
4 ± 8.6 (0–60) **
45 (18.9)
95 (39.9)
76 (31.9)
61 (25.6)
59 (24.8)
22 (9.2)
0.5 ± 0.8 (0–6) **
12.7 ± 5.4 (5–30) **
22.7 ± 16 (2–80) **
177 (74.4)
31 (13)
172 (72.3)
42 (17.6)

33 (56.9)
25 (43.1)
61.3 ± 15.9 (24–92) **
27 ± 3.9 (21–37) **
51 (87.6)
11 ± 15.8 (0–60) **
14 (24.1)
19 (32.8)
19 (32.8)
25 (43.1)
13 (22.4)
31 (53.4)
1.8 ± 2.7 (0–15) **
11.2 ± 4.2 (6–20) **
32 ± 23 (3–130) **
48 (82.8)
6 (10.3)
20 (34.5)
8 (13.8)

103 (43.3)
105 (44.1)
30 (12.6)

16 (27.6)
35 (60.3)
7 (12.1)

0.639 b
0.013 b
0.004 a
0.001 b
0.477 a
0.393 a
1.000 a
0.014 a
0.836 a
<0.001 a
<0.001 b
0.097 b
0.001 b
0.242 a
0.740 a
0.001 a
0.612 a
0.060 a

0.020 a
107 (45.5)
28 (11.8)

38 (65.5)
4 (6.9)
0.962 a

95 (39.9)
101 (42.4)
42 (17.6)

22 (37.9)
26 (44.8)
10 (17.2)
0.002 a

52 (21.8)
121 (50.8)
58 (24.4)
7 (2.9)

3 (5.2)
26 (44.8)
24 (41.4)
5 (8.6)

43 (18.1)
16 (6.7)
8 (3.4)

16 (27.6)
21 (36.2)
7 (12.1)

0.149 a
0.001 a
0.014 a

ASA: American Society of Anesthesiologists. ERCP: Endoscopic Retrograde Cholangiopancreatography, CBD: Common
Bile Duct, BMI: Body Mass Index kg/m2, min: minutes, mg/dL: milligrams per decilitre, mm: millimeter, *mean ± SD.
**minimum-maxiımum values, aChi-squared test, bMann–Whitney U test.
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Table 4. Multivariable logistic regression analysis of risk factors for post-ERCP cholangitis.
95% CI
p value

OR

Lower

Upper

Cholangiocarcinoma

0.004

15.722

2.434

101.552

ASA score

0.024

2.875

1.146

7.214

Increase in bilirubin

0.043

1.813

1.018

3.227

BMI

0.048

1.154

1.001

1.330

Procedure duration (min)

0.049

1.027

1.000

1.055

Hospitalization (days)

0.428

1.017

0.976

1.060

None

0.45

1.0 (reference)

Plastic stent

0.25

1.952

0.617

6.173

Metallic stent

0.85

0.788

0.093

6.666

Stent type

BMI: Body Mass Index kg/m2, CI: Confidence Interval, OR: Odds Ratio, min: minutes.

(ASGE) guideline recommendations, antibiotic usage is
not routinely recommended before ERCP, but one should
consider initiating antibiotics for patients at high risks,
like suspicion of incomplete biliary drainage [26]. On the
one hand, oral care, washing the duodenum lumen, and
scope working channel could prevent microorganism
inoculation in the bile duct and consequently reduce the
cholangitis rate [27]. However, adding antibiotics to the
contrast dye did not change the post-ERCP cholangitis
incidence rate [28]. These suggested interventions need
confirmation with prospective, more extensive studies.
Using a retrospective cohort was one of the main
limitations of our study. This study design comes with the
possibility of selection bias. Another limitation was that the
studied population consisted of a relatively small number
of patients. Therefore, we may have underestimated the
extent of post-ERCP cholangitis-related factors and missed
small statistical changes. Given that we conducted this
study at a tertiary healthcare facility, it is possible that we
included patients in more severe conditions. Consequently,
the generalizability of our results to community-based
healthcare facilities remains unclear.

Despite the limitations, we analyzed only one
endoscopist’s ERCPs to eliminate the heterogeneity that
may arise from the experience of different endoscopists.
We also use renewed ERCP scopes and fixed scope
reprocessing procedures such as instrument washing and
drying units to rule out potential confounds according
to international guidelines [29]. Lastly, patients with
unreliable and inconsistent data in our hospital’s electronic
records were meticulously eliminated from the study.
In conclusion, patients with high ASA and BMI scores,
prolonged total procedure time, and bilirubin increase
after the procedure were at risk for developing postERCP cholangitis. Successful removal of the biliary stone
with the balloon was protective against cholangitis. Our
research was exploratory. Thus, future studies are needed
to evaluate whether measures against these risk factors will
reduce cholangitis rates.
Conflict of interest
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